nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
A comprehensive approach to therapy of haematological malignancies in older patients
|
Cordoba, Raul |
|
|
|
11 |
p. e840-e852 |
artikel |
2 |
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial
|
Goldschmidt, Hartmut |
|
|
|
11 |
p. e810-e821 |
artikel |
3 |
A junior doctor on the other side of a bone marrow transplantation
|
Marjot, Jack |
|
|
|
11 |
p. e793 |
artikel |
4 |
Alternative donors: a match for matched sibling donors?
|
Inamoto, Yoshihiro |
|
|
|
11 |
p. e545-e546 |
artikel |
5 |
Am I a scientist?
|
Kerep, Ana Zelić |
|
|
|
11 |
p. e878 |
artikel |
6 |
An alternative to radiotherapy in consolidation of brain lymphoma
|
Schiff, David |
|
2017 |
|
11 |
p. e498-e499 |
artikel |
7 |
Analysis of an algorithm incorporating limited and whole-leg assessment of the deep venous system in symptomatic outpatients with suspected deep-vein thrombosis (PALLADIO): a prospective, multicentre, cohort study
|
Ageno, Walter |
|
2015 |
|
11 |
p. e474-e480 nvt p. |
artikel |
8 |
Antibody-drug conjugates: when chemotherapy meets immuno-oncology
|
Mina, Roberto |
|
|
|
11 |
p. e778-e779 |
artikel |
9 |
Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis
|
Anagnostou, Theodora |
|
|
|
11 |
p. e816-e826 |
artikel |
10 |
A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise
|
Lue, Jennifer K |
|
|
|
11 |
p. e838-e850 |
artikel |
11 |
A rare blood disorder that created a watercolour storytelling movement
|
Keys, Kris |
|
|
|
11 |
p. e790-e791 |
artikel |
12 |
Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis
|
Bartelink, Imke H |
|
2016 |
|
11 |
p. e526-e536 nvt p. |
artikel |
13 |
Authors' reply to comment Blood transfusion strategies in elderly patients
|
Simon, Geoff I |
|
2017 |
|
11 |
p. e508 |
artikel |
14 |
Authors' reply to comment What should be the endpoints of a symptomatic drug and its control?
|
Mesa, Ruben |
|
2017 |
|
11 |
p. e508-e509 |
artikel |
15 |
Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies
|
Thanarajasingam, Gita |
|
2018 |
|
11 |
p. e563-e598 |
artikel |
16 |
Biosimilars: when a negative study can be positive
|
Link, Brian K |
|
2018 |
|
11 |
p. e500-e501 |
artikel |
17 |
Blood transfusion in sub-Saharan Africa: walking a tightrope
|
Mpimbaza, Arthur |
|
|
|
11 |
p. e774-e775 |
artikel |
18 |
Blueprint for greater security of immunoglobulins for patients in Canada
|
Sher, Graham D |
|
|
|
11 |
p. e804-e805 |
artikel |
19 |
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial
|
Cheson, Bruce D |
|
|
|
11 |
p. e808-e815 |
artikel |
20 |
Burning out—whose responsibility is it?
|
Kerep, Ana Zelić |
|
|
|
11 |
p. e806 |
artikel |
21 |
Can we not bleed?
|
The Lancet Haematology, |
|
2016 |
|
11 |
p. e497- 1 p. |
artikel |
22 |
Cardiovascular disease after Hodgkin's lymphoma: a role for screening
|
Kupeli, Serhan |
|
2015 |
|
11 |
p. e461-e462 nvt p. |
artikel |
23 |
Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials
|
Maraldo, Maja V |
|
2015 |
|
11 |
p. e492-e502 nvt p. |
artikel |
24 |
Challenges facing women and girls with bleeding disorders
|
Doherty, Dearbhla |
|
|
|
11 |
p. e875-e876 |
artikel |
25 |
Changes in dynamics of excess mortality rates and net survival after diagnosis of follicular lymphoma or diffuse large B-cell lymphoma: comparison between European population-based data (EUROCARE-5)
|
Mounier, Morgane |
|
2015 |
|
11 |
p. e481-e491 nvt p. |
artikel |
26 |
Changing the face of clinical trials
|
The Lancet Haematology, |
|
|
|
11 |
p. e540 |
artikel |
27 |
Changing views on adverse event reporting
|
Flores, Beatriz |
|
2018 |
|
11 |
p. e506-e507 |
artikel |
28 |
Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy
|
Joly, Bérangère S |
|
2016 |
|
11 |
p. e537-e546 nvt p. |
artikel |
29 |
Chimeric antigen receptor T-cell therapy for acute lymphocytic leukaemia: where are we in 2020?
|
Laetsch, Theodore W |
|
|
|
11 |
p. e778-e779 |
artikel |
30 |
Clive Smith: pushing sporting boundaries
|
Smith, Clive |
|
|
|
11 |
p. e877 |
artikel |
31 |
Comparison of international guideline recommendations for the diagnosis of pulmonary embolism
|
Falster, Casper |
|
|
|
11 |
p. e922-e935 |
artikel |
32 |
Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
|
Castillo, Jorge J |
|
|
|
11 |
p. e827-e837 |
artikel |
33 |
Correction to Lancet Haematol 2015; 2: e498
|
|
|
2015 |
|
11 |
p. e464- 1 p. |
artikel |
34 |
Correction to Lancet Haematol 2015; 2: e364
|
|
|
2015 |
|
11 |
p. e464- 1 p. |
artikel |
35 |
Correction to Lancet Haematol 2021; 8: e711–22
|
|
|
|
|
11 |
p. e789 |
artikel |
36 |
Correction to Lancet Haematol 2021; 8: e67–79
|
|
|
|
|
11 |
p. e789 |
artikel |
37 |
Correction to Lancet Haematol 2021; 8: e55–66
|
|
|
|
|
11 |
p. e789 |
artikel |
38 |
Correction to Lancet Haematol 2020; 7: e456–68
|
|
|
|
|
11 |
p. e785 |
artikel |
39 |
Correction to Lancet Haematol 2020; 7: e715–23
|
|
|
|
|
11 |
p. e785 |
artikel |
40 |
Correction to Lancet Haematol 2019; 6: e489
|
|
|
|
|
11 |
p. e549 |
artikel |
41 |
Correction to Lancet Haematol 2023; 10: e333–45
|
|
|
|
|
11 |
p. e874 |
artikel |
42 |
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation study
|
Pabst, Thomas |
|
|
|
11 |
p. e902-e912 |
artikel |
43 |
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
|
Lübbert, Michael |
|
|
|
11 |
p. e879-e889 |
artikel |
44 |
Decitabine versus intensive chemotherapy induction for older patients with acute myeloid leukaemia: a futile but successful trial
|
Montesinos, Pau |
|
|
|
11 |
p. e866-e867 |
artikel |
45 |
Defining low-risk high hyperdiploidy in patients with paediatric acute lymphoblastic leukaemia: a retrospective analysis of data from the UKALL97/99 and UKALL2003 clinical trials
|
Enshaei, Amir |
|
|
|
11 |
p. e828-e839 |
artikel |
46 |
Definition of functional iron deficiency and intravenous iron supplementation
|
Eisenga, Michele F |
|
2016 |
|
11 |
p. e504- 1 p. |
artikel |
47 |
Definition of functional iron deficiency and intravenous iron supplementation – Author's reply
|
Khalafallah, Alhossain A |
|
2016 |
|
11 |
p. e504-e505 nvt p. |
artikel |
48 |
Disparities in health care at stake in the 2020 US election
|
The Lancet Haematology, |
|
|
|
11 |
p. e773 |
artikel |
49 |
Dose-adjusted EPOCH-R plus venetoclax: a toxic bend in the road to improving R-CHOP?
|
Chamuleau, Martine E D |
|
|
|
11 |
p. e781-e783 |
artikel |
50 |
Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study
|
Eapen, Mary |
|
|
|
11 |
p. e585-e596 |
artikel |
51 |
Efficacy and safety of thalidomide for the treatment of severe recurrent epistaxis in hereditary haemorrhagic telangiectasia: results of a non-randomised, single-centre, phase 2 study
|
Invernizzi, Rosangela |
|
2015 |
|
11 |
p. e465-e473 nvt p. |
artikel |
52 |
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
|
Ogura, Michinori |
|
2018 |
|
11 |
p. e543-e553 |
artikel |
53 |
Elastic compression therapy to prevent post-thrombotic syndrome
|
Labropoulos, Nicos |
|
2018 |
|
11 |
p. e494-e495 |
artikel |
54 |
Embracing the complexity in cancer therapy
|
The Lancet Haematology, |
|
2018 |
|
11 |
p. e493 |
artikel |
55 |
Emicizumab prophylaxis in patients with acquired haemophilia A (GTH-AHA-EMI): an open-label, single-arm, multicentre, phase 2 study
|
Tiede, Andreas |
|
|
|
11 |
p. e913-e921 |
artikel |
56 |
Empowering patients with venous thromboembolism
|
The Lancet Haematology, |
|
|
|
11 |
p. e865 |
artikel |
57 |
European Congress on Thrombosis and Haemostasis 2019
|
del Pozo Martín, Yaiza |
|
|
|
11 |
p. e550 |
artikel |
58 |
Exercise training: a prescription for sickle-cell disease?
|
Kato, Gregory J |
|
2018 |
|
11 |
p. e502-e503 |
artikel |
59 |
Finally, what we have been waiting for: evidence that transfusion of RBCs at the extreme of the storage spectrum is safe
|
Gehrie, Eric A |
|
2017 |
|
11 |
p. e504-e505 |
artikel |
60 |
Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial
|
Popat, Uday R |
|
2018 |
|
11 |
p. e532-e542 |
artikel |
61 |
Gilbert's syndrome in haemopoietic cell transplantation
|
Arora, Mukta |
|
2016 |
|
11 |
p. e500-e501 nvt p. |
artikel |
62 |
Haematopoietic stem-cell transplantation in older adults: geriatric assessment, donor considerations, and optimisation of care
|
Kennedy, Vanessa E |
|
|
|
11 |
p. e853-e861 |
artikel |
63 |
Have cancer, will travel
|
Downs, David |
|
|
|
11 |
p. e792 |
artikel |
64 |
Histological transformation and secondary malignancies in follicular lymphoma
|
Vitolo, Umberto |
|
2018 |
|
11 |
p. e496-e497 |
artikel |
65 |
Hodgkin lymphoma in pregnancy: good news for clinicians and women
|
Codacci-Pisanelli, Giovanni |
|
|
|
11 |
p. e541-e542 |
artikel |
66 |
Iberdomide plus dexamethasone in heavily pretreated late-line relapsed or refractory multiple myeloma (CC-220-MM-001): a multicentre, multicohort, open-label, phase 1/2 trial
|
Lonial, Sagar |
|
|
|
11 |
p. e822-e832 |
artikel |
67 |
Iberdomide with dexamethasone: a new backbone for myeloma treatment?
|
Rodriguez-Otero, Paula |
|
|
|
11 |
p. e799-e801 |
artikel |
68 |
Immunohaematological complications in patients with sickle cell disease after haemopoietic progenitor cell transplantation: a prospective, single-centre, observational study
|
Allen, Elizabeth S |
|
2017 |
|
11 |
p. e553-e561 |
artikel |
69 |
Immunotherapy for older patients with classic Hodgkin lymphoma
|
Connors, Joseph M |
|
|
|
11 |
p. e776-e777 |
artikel |
70 |
Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study
|
Kelly, Kevin R |
|
|
|
11 |
p. e794-e807 |
artikel |
71 |
Individually shortened duration versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome: a cost-effectiveness analysis
|
Amin, Elham E |
|
2018 |
|
11 |
p. e512-e519 |
artikel |
72 |
Inhibition of the CD47–SIRPα axis by TTI-621 to treat relapsed or refractory mycosis fungoides or Sézary syndrome
|
Stadler, Rudolf |
|
|
|
11 |
p. e779-e781 |
artikel |
73 |
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study
|
Querfeld, Christiane |
|
|
|
11 |
p. e808-e817 |
artikel |
74 |
Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: two open-label, randomised controlled trials
|
Stoffel, Nicole U |
|
2017 |
|
11 |
p. e524-e533 |
artikel |
75 |
Iron deficiency anaemia—an ongoing challenge
|
The Lancet Haematology, |
|
|
|
11 |
p. e797 |
artikel |
76 |
Isolated IgG4-related disease of the left maxillary antrum
|
Ramani, Pratibha |
|
|
|
11 |
p. e862 |
artikel |
77 |
Is pharmacokinetic guidance a must in busulfan regimens?
|
Kanda, Yoshinobu |
|
2018 |
|
11 |
p. e498-e499 |
artikel |
78 |
Join us at The Lancet Clinic
|
Kleinert, Sabine |
|
2015 |
|
11 |
p. e463- 1 p. |
artikel |
79 |
Keeping the blood flowing during times of disaster
|
The Lancet Haematology, |
|
2017 |
|
11 |
p. e497 |
artikel |
80 |
Lenalidomide maintenance therapy in previously treated chronic lymphocytic leukaemia (CONTINUUM): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Chanan-Khan, Asher A |
|
2017 |
|
11 |
p. e534-e543 |
artikel |
81 |
Life is a PAINting
|
Nazaire, Hertz |
|
|
|
11 |
p. e787-e788 |
artikel |
82 |
Limits of registry data to understand survival disparities in lymphoma
|
Olszewski, Adam J |
|
2015 |
|
11 |
p. e459-e460 nvt p. |
artikel |
83 |
Living longer and better with haematological malignancies: a promise for older adults too?
|
Extermann, Martine |
|
|
|
11 |
p. e784-e786 |
artikel |
84 |
Maintenance lenalidomide could be most relevant after first-line therapy
|
Chang, Julie E |
|
2017 |
|
11 |
p. e502-e503 |
artikel |
85 |
Mantle cell lymphoma: minimal residual disease outcomes
|
Vose, Julie M |
|
|
|
11 |
p. e775-e776 |
artikel |
86 |
Maximising response depth is important in multiple myeloma
|
Chen, Xiaoyi |
|
|
|
11 |
p. e798-e799 |
artikel |
87 |
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial
|
Costa, Luciano J |
|
|
|
11 |
p. e890-e901 |
artikel |
88 |
Moderate-intensity endurance-exercise training in patients with sickle-cell disease without severe chronic complications (EXDRE): an open-label randomised controlled trial
|
Gellen, Barnabas |
|
2018 |
|
11 |
p. e554-e562 |
artikel |
89 |
Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group
|
Le Gouill, Steven |
|
|
|
11 |
p. e798-e807 |
artikel |
90 |
Mortality benefits of thromboprophylaxis
|
Eikelboom, John |
|
|
|
11 |
p. e783 |
artikel |
91 |
Mortality benefits of thromboprophylaxis – Authors' reply
|
Klemen, Nicholas D |
|
|
|
11 |
p. e783-e784 |
artikel |
92 |
Mortality outcomes after busulfan-containing conditioning treatment and haemopoietic cell transplantation in patients with Gilbert's syndrome: a retrospective cohort study
|
McDonald, George B |
|
2016 |
|
11 |
p. e516-e525 nvt p. |
artikel |
93 |
MRD-guided treatment cessation in multiple myeloma
|
Derman, Benjamin A |
|
|
|
11 |
p. e867-e868 |
artikel |
94 |
Multi-organ graft-versus-host disease after nivolumab for relapsed Hodgkin lymphoma: the role of plasma exchange
|
Amerikanou, Rodothea |
|
|
|
11 |
p. e862 |
artikel |
95 |
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes
|
Sasaki, Koji |
|
|
|
11 |
p. e872 |
artikel |
96 |
Non-haematological grade 1 and 2 adverse events of frontline CPX-351 in patients with myelodysplastic syndromes – Authors' reply
|
Peterlin, Pierre |
|
|
|
11 |
p. e872-e873 |
artikel |
97 |
Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study
|
Maggen, Charlotte |
|
|
|
11 |
p. e551-e561 |
artikel |
98 |
Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial
|
Watanabe, Takashi |
|
2018 |
|
11 |
p. e520-e531 |
artikel |
99 |
Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis
|
Shouval, Roni |
|
|
|
11 |
p. e573-e584 |
artikel |
100 |
Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
|
San-Miguel, Jesús F |
|
2016 |
|
11 |
p. e506-e515 nvt p. |
artikel |
101 |
Panobinostat plus bortezomib and dexamethasone for relapsed myeloma
|
Pratt, Guy |
|
2016 |
|
11 |
p. e498-e499 nvt p. |
artikel |
102 |
Place-of-care manufacturing of gene therapies
|
Adair, Jennifer E |
|
|
|
11 |
p. e807-e808 |
artikel |
103 |
Postnatal treatment for children with fetal and neonatal alloimmune thrombocytopenia: a multicentre, retrospective, cohort study
|
de Vos, Thijs W |
|
|
|
11 |
p. e844-e853 |
artikel |
104 |
Prioritising health equity alongside donation safety
|
Fingrut, Warren B |
|
|
|
11 |
p. e802-e803 |
artikel |
105 |
Prioritising health equity alongside donation safety – Authors' reply
|
Koh, Mickey B C |
|
|
|
11 |
p. e803-e804 |
artikel |
106 |
Rahul Bhargava: making bone marrow transplantation accessible in India
|
Wilkinson, Emma |
|
|
|
11 |
p. e809 |
artikel |
107 |
Rapidly loading emicizumab without immunosuppression in acquired haemophilia
|
Ragni, Margaret V |
|
|
|
11 |
p. e870-e871 |
artikel |
108 |
Real-world evidence in safety assessment of new treatments
|
Smedby, Karin E |
|
2018 |
|
11 |
p. e510-e511 |
artikel |
109 |
Red blood cell alloimmunisation in patients with sickle cell disease
|
Volt, Fernanda |
|
2017 |
|
11 |
p. e506-e507 |
artikel |
110 |
Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial
|
Cook, Richard J |
|
2017 |
|
11 |
p. e544-e552 |
artikel |
111 |
Redefining high hyperdiploid B-cell acute lymphoblastic leukaemia
|
Lafage-Pochitaloff, Marina |
|
|
|
11 |
p. e783-e784 |
artikel |
112 |
Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies
|
Chakraborty, Rajshekhar |
|
|
|
11 |
p. e936-e940 |
artikel |
113 |
Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial
|
Lee, Jong Wook |
|
|
|
11 |
p. e562-e572 |
artikel |
114 |
Science over stigma: the need for evidence-based blood donation policies for men who have sex with men in the USA
|
Skelly, Ashwin N |
|
|
|
11 |
p. e779-e782 |
artikel |
115 |
Should unrelated haematopoietic progenitor cell donors be tested for CD36 in Japan?
|
Sato, Tomohiko |
|
|
|
11 |
p. e802 |
artikel |
116 |
Sophie Uyoga–reducing sickle cell stigma in Africa
|
Kirby, Tony |
|
|
|
11 |
p. e786 |
artikel |
117 |
Standardising busulfan dosage for children and young adults
|
Gorin, Norbert-Claude |
|
2016 |
|
11 |
p. e502-e503 nvt p. |
artikel |
118 |
Stem cell stimulation continues to pay off in aplastic anaemia
|
Scheinberg, Phillip |
|
|
|
11 |
p. e543-e544 |
artikel |
119 |
Stem cell transplantation in sickle-cell disease
|
Sheth, Sujit |
|
|
|
11 |
p. e547-e548 |
artikel |
120 |
Targeting CD70 in acute myeloid leukaemia: an emerging therapeutic angle in combinatorial treatment
|
Fathi, Amir T |
|
|
|
11 |
p. e868-e870 |
artikel |
121 |
Telehealth and digital equity for older people
|
The Lancet Haematology, |
|
|
|
11 |
p. e777 |
artikel |
122 |
Thalidomide for hereditary haemorrhagic telangiectasia
|
Franchini, Massimo |
|
2015 |
|
11 |
p. e457-e458 nvt p. |
artikel |
123 |
The cost of cure
|
Schmiegelow, Kjeld |
|
2018 |
|
11 |
p. e504-e505 |
artikel |
124 |
The effect of blood transfusion on outcomes among African children admitted to hospital with Plasmodium falciparum malaria: a prospective, multicentre observational study
|
Ackerman, Hans |
|
|
|
11 |
p. e789-e797 |
artikel |
125 |
The influence of drug prices, new availability of inexpensive generic imatinib, new approvals, and post-marketing research on the treatment of chronic myeloid leukaemia in the USA
|
Kantarjian, Hagop |
|
|
|
11 |
p. e854-e861 |
artikel |
126 |
The need to assess financial adverse events
|
Nastoupil, Loretta J |
|
2018 |
|
11 |
p. e508-e509 |
artikel |
127 |
The rising cost of orphan drugs
|
The Lancet Haematology, |
|
2015 |
|
11 |
p. e456- 1 p. |
artikel |
128 |
Treatment of iron deficiency is getting trendy
|
Auerbach, Michael |
|
2017 |
|
11 |
p. e500-e501 |
artikel |
129 |
UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial
|
Benjamin, Reuben |
|
|
|
11 |
p. e833-e843 |
artikel |
130 |
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency
|
Sato, Tomohiko |
|
|
|
11 |
p. e787 |
artikel |
131 |
Under-recognition of measurement and management of serum ferritin among populations at high risk of iron deficiency – Authors' reply
|
Jefferds, Maria Elena |
|
|
|
11 |
p. e787-e788 |
artikel |
132 |
Venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma: a single-arm, multicentre, phase 1 study
|
Rutherford, Sarah C |
|
|
|
11 |
p. e818-e827 |
artikel |
133 |
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial
|
Ferreri, Andrés J M |
|
2017 |
|
11 |
p. e510-e523 |
artikel |